CEO: Novartis plans big restructuring
On second thought, let's restructure the whole company: In October, Novartis announced some job cuts and management changes. Now, CEO Daniel Vasella (photo) says he's working on a sweeping overhaul of his company's org chart. He's not ready to disclose details, but he did tell the Wall Street Journal that he wants to remove several layers of management so that employees can make decisions more quickly.
Vasella says Novartis needs to become less bureaucratic to handle the drug industry's many challenges, which we probably don't need to name here, but will anyway: generic competition, cautious regulators, cost-conscious payers.
This second round of restructuring will involve more job cuts, Vasella says, but he didn't specify how many. More details on the plan are forthcoming by mid-December, with further info coming in February.
- read the report from the Wall Street Journal
UPDATE: Novartis announced on December 12 that it would cut 2,500 jobs. Report
ALSO: Take a look at Novartis' pipeline. Report
Related Articles:
Top 5 layoffs of 2007. Report
Lagging sales spur Novartis layoffs. Report
Novartis makes the "Biggest Splash". Report
Novartis bankrolls a drug manufacturing revolution. Report
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

